Hodgkin’s Lymphoma Market

Market Overview:

The 7 major Hodgkin’s lymphoma markets reached a value of US$ 6.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 18.9 Billion by 2034, exhibiting a growth rate (CAGR) of 10.29% during 2024-2034.

The Hodgkin’s lymphoma market has been comprehensively analyzed in IMARC's new report titled "Hodgkin’s Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hodgkin's lymphoma refers to a type of oncological disease that affects the lymphatic system, which is part of the body's immune system. The illness is characterized by the presence of large, atypical white blood cells within the lymph nodes. These cells contribute to the growth of the cancerous mass and the immune response associated with the illness. The most common symptom of the ailment is painless swelling of lymph nodes, mainly in the armpits, neck, or groin. Individuals suffering from this disease may also experience loss of appetite, fatigue, fever, night sweats, unexplained weight loss, itching, a persistent cough or feeling of breathlessness, etc. Hodgkin's lymphoma is typically diagnosed through a combination of medical history assessment, underlying indication review, and physical examination. During a physical exam, the healthcare provider will closely check any signs of enlarged lymph nodes, swelling, or other abnormalities. Blood tests are also recommended to measure certain disease markers, such as erythrocyte sedimentation rate and C-reactive protein, in patients. Additionally, a biopsy is generally utilized to confirm a diagnosis of the condition.

The increasing cases of genetic disorders, causing an alteration in the DNA of B lymphocytes, which are a particular form of white blood cells, are primarily driving the Hodgkin's lymphoma market. In addition to this, the rising incidence of several associated risk factors, including a weakened immune system, family history, chronic inflammation, Epstein-Barr virus infections, etc., is also propelling the market growth. Moreover, the emerging popularity of external beam radiation therapy on account of its numerous benefits over conventional chemotherapies, such as targeted treatment, fewer systemic side effects, and convenience, is acting as another significant growth-inducing factor. Additionally, the escalating application of stem cell transplantation to treat individuals suffering from relapsed or refractory disease conditions is further creating a positive outlook for the market. This procedure helps to replace cancerous cells with healthy blood-forming cells to reestablish a normal blood cell population. Furthermore, the inflating adoption of targeted therapies, like monoclonal antibodies, which are specifically designed to stop the growth and spread of tumors, is expected to drive the Hodgkin's lymphoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the Hodgkin’s lymphoma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Hodgkin’s lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Hodgkin’s lymphoma market in any manner.

Recent Developments:

• In June 2024, Takeda and Pfizer announced that the German Hodgkin Study Group (GHSG) will present positive results from the Phase 3 HD21 trial of ADCETRIS (brentuximab vedotin) in combination with chemotherapy as a late-breaking oral presentation at the 60th American Society of Clinical Oncology (ASCO) Annual Meeting (LBA7000) and the 29th European Hematology Association (EHA) Annual Meeting (S225). The GHSG's four-year investigation revealed higher progression-free survival and enhanced patient tolerability when compared to the current standard of care regimen utilized in Europe in this context. 
• In September 2023, Affimed N.V. reported that the FDA had given fast track designation to the combination of its innate cell engager (ICE) AFM13 and AlloNK for the possible treatment of relapsed/refractory Hodgkin lymphoma. This combination medication is in Phase 2 development and will be tested in Affimed's LuminICE-203 research (NCT05883449), which has gained IND clearance. The study also includes an exploratory cohort of CD30-positive peripheral T-cell lymphoma patients.

Key Highlights:

• Hodgkin lymphoma affects around one in every 25,000 people each year, accounting for slightly less than 1% of all malignancies that occur worldwide.
• Children under the age of five are extremely unlikely to have Hodgkin lymphoma. However, it is the most common cancer diagnosed in teenagers aged 15 to 19 years.
• Males are more prone than females to develop Hodgkin lymphoma, particularly in youngsters, with boys accounting for 85% of all cases.
• Females had a 2.9 times lower age-related incidence rate than males between the ages of 5 and 9.
• The 5- and 10-year survival rates are expected to be about 85% and 80%, respectively.

Drugs:

Adcetris (Brentuximab vedotin) is an antibody-drug conjugate (ADC) composed of an anti-CD30 monoclonal antibody linked to a microtubule disrupting chemical, monomethyl auristatin E (MMAE), via a protease-cleavable linker and Seagen's patented technology. The ADC uses a linker system that is designed to be stable in the bloodstream yet release MMAE when internalized by CD30-positive tumor cells.

AFM13 is a first-in-class innate cell engager (ICE) that specifically engages the innate immune system to eliminate CD30-positive hematologic malignancies. AFM13 increases targeted and selective killing of CD30-positive tumor cells, leveraging the innate immune system's capabilities by attracting and activating natural killer (NK) cells and macrophages.

Camidanlumab tesirine is an ADC comprised of a human monoclonal antibody that binds to CD25 (HuMax-TAC, licensed from Genmab A/S), conjugated to the pyrrolobenzodiazepine (PBD) dimer payload, tesirine. After binding to a CD25-expressing cell, camidanlumab tesirine is internalized into the cell, where enzymes release the PBD-based warhead, killing the cell.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Hodgkin’s lymphoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Hodgkin’s lymphoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Hodgkin’s lymphoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Hodgkin’s lymphoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the Hodgkin’s lymphoma market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the Hodgkin’s lymphoma market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of Hodgkin’s lymphoma across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Hodgkin’s lymphoma by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Hodgkin’s lymphoma by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with Hodgkin’s lymphoma across the seven major markets?
• What is the size of the Hodgkin’s lymphoma patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of Hodgkin’s lymphoma?
• What will be the growth rate of patients across the seven major markets?
   

Hodgkin’s Lymphoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Hodgkin’s lymphoma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Hodgkin’s lymphoma market?
• What are the key regulatory events related to the Hodgkin’s lymphoma market?
• What is the structure of clinical trial landscape by status related to the Hodgkin’s lymphoma market?
• What is the structure of clinical trial landscape by phase related to the Hodgkin’s lymphoma market?
• What is the structure of clinical trial landscape by route of administration related to the Hodgkin’s lymphoma market?